The S1PR modulators are currently positioned to serve as a great treatment option for patients with moderate disease who are hesitant to escalate to a biologic treatment.
The final quarterly issue of the year touches on head-to-head trial data, a new treatment for erosive esophagitis, an ulcerative colitis agent, and the latest ACG recommendations for Celiac disease.e.
While discussing a review of noninvasive options, the gastroenterologist addresses the growing interest in non-colonoscopy screening and surveillance methods.